LTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%

MT Newswires Live

Mar 05

LTR Pharma (ASX:LTP) has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.

The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.

The initial phase two results are expected in the second quarter, the filing added.

The company's shares rose around 7% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2617598609"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617598609\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617598609?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617598609","market":"sg","top_or_hot":-1,"title":"LTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%","media":"MT Newswires Live","content":"<html><body><p> LTR Pharma (ASX:LTP) has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.</p><p>The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.</p><p>The initial phase two results are expected in the second quarter, the filing added.</p><p>The company's shares rose around 7% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLTR Pharma Completes Recruitment for Phase Two Study of Spontan; Shares Up 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-05 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> LTR Pharma (ASX:LTP) has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.</p><p>The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.</p><p>The initial phase two results are expected in the second quarter, the filing added.</p><p>The company's shares rose around 7% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2617598609","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617598609","pubTimestamp":1772669667,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"LTR Pharma  has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.The initial phase two results are expected in the second quarter, the filing added.The company's shares rose around 7% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","LTP.AU":"LTR PHARMA LTD"},"translate_title":"LTR Pharma完成Spontan二期研究的招募；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTP.AU":1},"content_text":"LTR Pharma (ASX:LTP) has completed enrollment for its phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray for erectile dysfunction, successfully recruiting 27 participants across three dose cohorts, according to a Thursday filing with the Australian bourse.The final cohort, which includes men aged 65 and older, is currently participating in a 15-day residential dosing period with Spontan and a control vardenafil tablet to collect essential pharmacokinetic data for dose optimization and future US Food and Drug Administration labeling, the filing said.The initial phase two results are expected in the second quarter, the filing added.The company's shares rose around 7% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}